Cynata Finishes Patient Enrolment for Phase 1 Trial of CYP-006TK

Cynata Finishes Patient Enrolment for Phase 1 Trial of CYP-006TK

By, Admin 10 April 2024

Cynata Therapeutics completes patient enrolment in phase 1 trial of CYP-006TK in diabetic foot ulcers

Overview

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, announced the completion of patient enrolment in its phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

About CYP-006TK

  • CYP-006TK is Cynata’s Cymerus iPSC1-derived MSC2 topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing. 
  • Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. 
  • In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if therapy is unsuccessful, amputation may be necessary. 
  • In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU.

About Trial 

The pre-specified sample size has now been reached, with a total of 30 patients with DFU randomised on a 1:1 basis to receive either: 

  • (i) CYP-006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or 
  • (ii) standard of care treatment throughout the study. 

In accordance with the study protocol, patients will be followed for 24 weeks following treatment initiation, which means that the last patient visit in this trial is expected to occur around September 2024.

Words from CMO: Cynata

Dr Jolanta Airey MD, Cynata’s chief medical officer, said: “We are delighted to have completed enrolment, and we extend our thanks to all of the investigators, study staff and patients for helping us to achieve this milestone. We recently announced very encouraging initial data from the first 16 patients enrolled in this trial after 10 weeks’ follow-up, with a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group, compared to 51.1% in the control group. We now look forward to completing the follow-up period and releasing the full results from this study shortly thereafter.”

Cynata Therapeutics Limited

Cynata Therapeutics Limited (is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!